Parkinson's disease is a nervous system disorder that impairs movement control. Parkinson's disease develops when nerve cells (neurons) in the substantia nigra (SN) portion of the brain become damaged or die. The condition often begins slowly and worsens over time. Trembling, muscular stiffness, difficulty in walking, keeping body balance, and coordination are the few symptoms associated with Parkinson's disease. As the condition progresses, difficulty in speaking & sleeping, thinking & memory issues, and behavioral changes may occur. According to Parkinson's Foundation, Parkinson's disease is found more frequently in men than women. A higher incidence was found among men with the risk of around 1.5 times greater in men than women.It is most typically found in those over the age of 60. Medications as well as other therapeutics such as exercise can help relieve some of the symptoms of Parkinson’s disease. Important therapeutic mode for patients with Parkinson’s disease is medications such as levodopa, safinamide, pramipexole, benztropine, and selegiline.
The global Parkinson’s disease therapeutic market is estimated to be valued at US$ 4,697.3 million in 2021 and is expected to exhibit a CAGR of 6.3% during the forecast period (2021-2028).
Figure 1. Global Parkinson’s Disease Therapeutic Market in Terms of Value (US$ million), By Region, 2021
Increasing approvals for drugs used in Parkinson’s disease is expected to drive the global Parkinson’s disease therapeutic market growth during forecast period
Rising drug approvals for treatment of Parkinson’s disease is projected to boost the market growth during the forecast period. For instance, in August 2019, Kyowa Kirin Co., Ltd. a Japanese pharmaceutical and biotechnology company announced the U.S. Food and Drug Administration (FDA) approval for medicine NOURIANZ (istradefylline). It is used as adjunctive therapeutic to levodopa/carbidopa in adult patients experiencing ‘OFF’ episodes with Parkinson’s disease (PD). An off episode in Parkinson's disease occurs when a patient's medicines are not working properly, resulting in an increase in PD symptoms such as tremor and walking difficulties. NOURIANZ (istradefylline) is an adenosine A2A receptor antagonist used in Parkinson’s disease in the U.S. The medicine provides a novel non-dopaminergic once-a-day oral therapeutic option for patients with Parkinson’s disease.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 4,697.3 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 6.3% | 2028 Value Projection: | US$ 7,195.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Parkinson’s Disease Therapeutic Market Share in Terms of Value (US$ Mn), By Drug Class, 2021
Robust pipeline of new drugs in development for Parkinson’s disease is projected to propel the market growth over the forecast period
Robust pipeline of new drugs in development for Parkinson’s disease is expected to propel the Parkinson’s disease therapeutic market growth over the forecast period. For instance, in October 2021, according to Vanderbilt University, drug candidate mGlu4 PAM AP-472 for Parkinson’s disease entered phase 1 clinical trials. The clinical trial was initiated by Appello Pharmaceuticals Inc., a clinical-stage therapeutics company focused on searching innovative early-stage drug candidates for patients with Parkinson’s disease. The mGlu4 PAM AP-472 is designed to operate in conjunction with an existing Parkinson's disease medication, levodopa.
Global Parkinson’s Disease Therapeutic Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic has a devastating influence on the lives of many families across the world, as well as healthcare institutions and the global economy. During the COVID-19 epidemic, patients had trouble in getting their regular Parkinson's disease therapeutics. For instance, in August 2020, according to International Parkinson and Movement Disorder Society, the impact of COVID-19 on the quality of healthcare reported by Parkinson's disease patients found that COVID-19 reduced the quality of healthcare as well as worsened the symptoms and interrupted the access to medication access for Parkinson’s disease patients. Access to PD medication were negatively impacted by closing the routine clinical space, faltering delivery systems, and the inability to access dispensaries or pay for medication.
Global Parkinson’s Disease Therapeutic Market: Restraint
Rising side effects associated with drugs used in Parkinson’s disease therapeutic is projected to hamper the market growth during the forecast period. The Parkinson’s disease drugs side effects will have a negative impact on patient’s lives and have to be kept under control along with the symptoms. Impulsive and compulsive behavior are possible side effects of some Parkinson’s disease medications and can have a significant impact on the affected person. In addition the available medications may have an effect of blocking the Parkinson’s medications or interact in a way making symptoms worse.
Key Players
Major players operating in the global Parkinson’s disease therapeutic market include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH.
Parkinson's disease is a movement disorder caused by a neurological condition. Tremor, slowness of movement, tight muscles, an unsteady walk, balance, and coordination issues are all common symptoms. Levodopa, Dopamine agonists, MAO-B inhibitors, and Anticholinergics are some of the medications used for the treatment of Parkinson’s disease. Levodopa (also called L-dopa) is the most commonly prescribed drug for Parkinson’s disease. It is useful in controlling the symptoms such as slow movements and stiff & rigid body parts. Medication allows the majority of patients to retain a high quality of life and surgery can help some people improve their symptoms. Parkinson's disease patients also observe decrease in another neurotransmitter known as norepinephrine. This molecule is required for the sympathetic nervous system to operate properly. Some of the body's autonomic activities are controlled by this system, including digestion, heart rate, blood pressure, and breathing. Some of the non-movement-related symptoms of Parkinson's disease are caused by a lack of norepinephrine. Exercise can considerably improve Parkinson's symptoms. Physical therapy, occupational therapy, and speech-language therapy can also assist with walking and balance issues, eating and swallowing difficulties, and speech disorders.
Market Dynamics
Market players are focusing on new product launches, which is expected to propel the Parkinson’s disease therapeutic market growth during the forecast period. For instance, in May 2020, Sunovion Pharmaceuticals Inc. a pharmaceutical company announced that it received the U.S. Food and Drug Administration (FDA) approval for KYNMOBI (apomorphine hydrochloride) Sublingual Film for the acute, intermittent treatment for OFF episodes (i.e. re-emergence or worsening of PD symptoms) in patients with Parkinson’s disease. KYNMOBI is available in different strengths such as 10mg, 15mg, 20mg, and 25mg.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients